Clinical trials: Cemiplimab
Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC)
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
This is a phase II, multicenter, open label, single arm, non-randomized trial using Simon's optimal two-stage design to evaluate the efficacy of cemiplimab in kidney transplant recipients with advanced cutaneous squamous cell…
- Conditions
- Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC), Advanced Cutaneous Squamous Cell Carcinoma, Kidney Transplant
- Trial name
- CONTRAC-2 (NCT07715734)
- Testing
- Cemiplimab, Prednisone, Sirolimus
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Washington University School of Medicine
Non-Small Cell Lung Cancer, Metastatic Lung Cancer
A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer
Current clinical trials testing the combination of immunotherapy with radiotherapy.
- Trial name
- REVIVE (NCT07603856)
- Testing
- Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Chicago
Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic CSCC, as assessed by overall response rate (ORR) and complete response rate…
- Conditions
- Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
- Trial name
- CERPASS (NCT04050436)
- Testing
- Cemiplimab, RP1
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 231 people
- Sponsor
- Replimune, Inc.
Cutaneous Squamous Cell Carcinoma
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
The primary objective of the study is to compare disease-free survival (DFS) of patients with high-risk cutaneous squamous cell carcinoma (CSCC) treated with adjuvant cemiplimab, versus those treated with placebo, after surgery…
- Trial name
- NCT03969004
- Testing
- Cemiplimab
- Where
- 166 sites in United States, Australia and 14 more
- Volunteers
- 415 people
- Sponsor
- Regeneron Pharmaceuticals
Clear Cell Renal Cell Carcinoma
Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
The purpose of this research is to test the safety of PD-1 inhibitor cemiplimab with or without LAG-3 inhibitor fianlimab, and see what effects (good and bad) of cemiplimab either alone or combined with fianlimab has on patients…
- Trial name
- LAG-BOOST (NCT07223541)
- Testing
- Cemiplimab 350 MG Intravenous Solution, Fianlimab 1600 MG Intravenous Solution
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Oklahoma
Locally Advanced Head and Neck Squamous Cell Carcinoma
Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this research study is to determine the safety and tolerability of two dosing schedules of cemiplimab given in combination with cisplatin and docetaxel induction chemotherapy (TPI) in patients with locally advanced…
- Trial name
- NCT05376553
- Testing
- Cemiplimab, Cisplatin, Docetaxel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Krzysztof Misiukiewicz
Stage III Prostate Cancer, Stage IIIA Prostate Cancer
Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer
This phase I trial studies the side effects of anti-PD-1 monoclonal antibody REGN2810 (REGN2810) and/or ipilimumab when given together with stereotactic body radiation therapy before surgery in treating participants with prostate…
- Conditions
- Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer
- Trial name
- NCT03477864
- Testing
- Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), Radical Prostatectomy
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Prostate Cancer Metastatic
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
The primary objective is to determine the safety and activity of combined hormonal chemoimmunotherapy in a single-arm phase II trial of REGN2810, androgen deprivation therapy (ADT), and docetaxel in patients with newly…
- Trial name
- NCT03951831
- Testing
- REGN2810, Degarelix, Leuprolide Acetate
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Mark Stein
Melanoma
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN2810, also known as cemiplimab (each individually called a "study drug" or called…
- Trial name
- NCT05352672
- Testing
- Fianlimab, Cemiplimab, Pembrolizumab
- Where
- 210 sites in United States, Argentina and 22 more
- Volunteers
- 1,546 people
- Sponsor
- Regeneron Pharmaceuticals
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
This study is researching an experimental drug called cemiplimab. The study is focused on Cutaneous Squamous Cell Carcinoma (CSCC) and Basal Cell Carcinoma (BCC).
- Trial name
- NCT03889912
- Testing
- Cemiplimab
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 97 people
- Sponsor
- Regeneron Pharmaceuticals
Adrenal Cortical Carcinoma
Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer
This clinical trial is a single-arm, non-randomized, prospective phase II study. The study aims to evaluate if the maintenance immunotherapy with cemiplimab in patients with AdrenoCortical Carcinoma (ACC), who obtained disease…
- Trial name
- INTERVAL (NCT07085572)
- Testing
- Cemiplimab
- Where
- Italy
- Volunteers
- 31 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Metastatic NSCLC - Non-Small Cell Lung Cancer
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
Metastatic non-small cell lung cancer is often treated with a combination of chemotherapy and immunotherapy. In patients over the age of 70, some are already in poor health and frail, requiring assistance with daily activities…
- Trial name
- NCT07020065
- Testing
- Cemiplimab, Carboplatin, Pemetrexed & Gemcitabine
- Where
- 18 sites in Switzerland
- Volunteers
- 156 people
- Sponsor
- Swiss Cancer Institute
Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasal Cavity Squamous Cell Carcinoma
- Trial name
- NCT06980038
- Testing
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokinetics of intravenous infusion of CP-506, a tumor agnostic Hypoxia Activated Prodrug in…
- Trial name
- NCT04954599
- Testing
- CP-506, Carboplatin, Immune checkpoint inhibitor
- Where
- 5 sites in Belgium, Netherlands and 1 more
- Volunteers
- 126 people
- Sponsor
- Maastricht University Medical Center
Breast Cancer
PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer
This proposal is for a Window of Opportunity (WOO) clinical trial using a novel combination of two Health Canada approved agents, cemiplimab (Libtayo) and dupilumab (Dupixent), for off label use in early-stage estrogen receptor…
- Trial name
- NCT05967884
- Testing
- Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- Ottawa Hospital Research Institute
Metastatic Neoplasm
A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Primary Objectives: Dose Escalation: To determine maximum tolerated dose (MTD) or maximum administered dose (MAD) and overall safety and tolerability profile of SAR441000 when administered intratumorally as monotherapy and in…
- Trial name
- NCT03871348
- Testing
- SAR441000, Cemiplimab REGN2810
- Where
- 19 sites in United States, Belgium and 4 more
- Volunteers
- 77 people
- Sponsor
- Sanofi
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
CemiplimAb Survivorship Epidemiology
The objectives of the study are: To describe the effectiveness of cemiplimab 350 mg administered every 3 weeks (Q3W) for treatment of patients with advanced (defined as locally advanced or metastatic [nodal or distant]) cutaneous…
- Trial name
- CASE (NCT03836105)
- Testing
- cemiplimab
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 287 people
- Sponsor
- Regeneron Pharmaceuticals
Metastatic NUT Carcinoma, Unresectable NUT Carcinoma
Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma
This phase II trial studies how well cemiplimab works in treating patients with nuclear protein of testis (NUT) carcinoma for which no treatment is currently available (incurable) and that has spread from where it first started…
- Trial name
- NCT07050186
- Testing
- Biopsy Procedure, Biospecimen Collection, Cemiplimab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
NSCLC
A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.
This is a phase II randomized study investigating whether a combination maintenance with Cemiplimab and OSE2101 (TEDOPI®) could increase ctDNA clearance rate versus standard maintenance therapy in HLA-A2 positive NSCLC patients…
- Trial name
- Cemited (NCT07264673)
- Testing
- Tedopi, Cemiplimab
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- Fondazione Ricerca Traslazionale
Non-small Cell Lung Cancer (NSCLC)
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
This is a Phase 1b/2 study evaluating the anti-PD1 antibody, cemiplimab, in combination with either S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), or S095029 (anti-NKG2A antibody) in adult participants with…
- Trial name
- NCT06162572
- Testing
- S095018, S095024, S095029
- Where
- 52 sites in United States, Australia and 11 more
- Volunteers
- 102 people
- Sponsor
- Servier Bio-Innovation LLC